Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501827 | 0.82 | TSHR (0.58) | EPHX2MEN1KMT2AMAPK1TSHR | |
| SCHEMBL5157481 | 0.79 | HSD11B1 (0.43) | EPHX2USP2SMN1; SMN2HSD11B1 | |
| SCHEMBL24716881 | 0.79 | SMN1; SMN2 (0.45) | MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL24716617 | 0.79 | SMN1; SMN2 (0.45) | MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL15746865 | 0.79 | SMN1; SMN2 (0.45) | MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL17314784 | 0.77 | SMN1; SMN2 (0.43) | MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL17314782 | 0.77 | SMN1; SMN2 (0.43) | MEN1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL2737895 | 0.76 | SMN1; SMN2 (0.47) | USP2SMN1; SMN2 | |
| SCHEMBL15561495 | 0.76 | SMN1; SMN2 (0.47) | USP2SMN1; SMN2 | |
| SCHEMBL5475967 | 0.76 | SMN1; SMN2 (0.47) | USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | EPHX2 2185/4885MEN1 1602/4885KMT2A 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.